US Stock MarketDetailed Quotes
ELOX Eloxx Pharmaceuticals
- 0.000
- 0.0000.00%
15min DelayClose Nov 4 16:00 ET
628.68Market Cap0.00P/E (TTM)
0.000High0.000Low144Volume0.000Open0.000Pre Close0.03Turnover0.01%Turnover Ratio0.00P/E (Static)3.14MShares1.74052wk High0.00P/B553.23Float Cap0.00052wk Low--Dividend TTM2.77MShs Float984.000Historical High--Div YieldTTM0.00%Amplitude0.000Historical Low0.000Avg Price1Lot Size
Eloxx Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 50.33%-3.45M | 78.80%-2.07M | 28.21%-6.81M | 9.02%-31.85M | 43.00%-5.66M | 8.46%-6.95M | 0.51%-9.75M | -23.50%-9.49M | -24.27%-35M | -112.75%-9.93M |
| Net income from continuing operations | 52.16%-3.59M | 59.12%-4.34M | 46.39%-6.23M | 45.95%-36.07M | 47.73%-6.32M | 24.05%-7.51M | 70.55%-10.62M | -33.66%-11.62M | -92.98%-66.73M | -97.32%-12.09M |
| Operating gains losses | -890.00%-495K | 103.85%4K | 55.19%419K | 109.87%45K | ---71K | 90.74%-50K | ---104K | --270K | ---456K | --0 |
| Depreciation and amortization | -0.53%188K | 42.31%185K | -6.06%186K | -27.60%695K | -11.88%178K | -32.26%189K | -60.73%130K | 33.78%198K | 68.13%960K | 38.36%202K |
| Other non cash items | 102.16%281K | -64.93%47K | -3.23%120K | -97.55%541K | 18.03%144K | 54.44%139K | -99.38%134K | 12.73%124K | 3,823.09%22.09M | -2.40%122K |
| Change In working capital | 41.86%-250K | 4,430.30%1.43M | -409.92%-1.91M | -268.75%-118K | -214.89%-270K | -276.23%-430K | -171.74%-33K | 210.41%615K | 99.06%-32K | 352.69%235K |
| -Change in prepaid assets | -51.76%206K | -50.44%397K | 50.64%-577K | -56.70%252K | 493.88%193K | -40.28%427K | 113.03%801K | -154.13%-1.17M | 122.14%582K | -112.28%-49K |
| -Change in payables and accrued expense | 59.77%-278K | 265.62%1.21M | -158.96%-1.16M | 13.49%244K | -164.76%-294K | -201.75%-691K | -1,522.22%-730K | 5,497.14%1.96M | 106.80%215K | 225.41%454K |
| -Change in other current liabilities | -7.23%-178K | -70.19%-177K | 0.57%-174K | 25.93%-614K | 0.59%-169K | 31.40%-166K | 63.51%-104K | -32.58%-175K | -65.14%-829K | -30.77%-170K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 50.33%-3.45M | 78.80%-2.07M | 28.21%-6.81M | 9.02%-31.85M | 43.00%-5.66M | 8.46%-6.95M | 0.51%-9.75M | -23.50%-9.49M | -24.27%-35M | -112.75%-9.93M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 585.42%233K | 300.00%14K | 200.00%11K | -103.21%-66K | 0 | 30.43%-48K | -100.33%-7K | -11K | -93.92%2.06M | -20K |
| Net PPE purchase and sale | 585.42%233K | 300.00%14K | 200.00%11K | 25.84%-66K | --0 | 30.43%-48K | ---7K | ---11K | ---89K | ---20K |
| Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --2.15M | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 585.42%233K | 300.00%14K | 200.00%11K | -103.21%-66K | --0 | 30.43%-48K | -100.33%-7K | ---11K | -93.92%2.06M | ---20K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 144.67%3.67M | 1.43M | -207.14%-7.5M | -82.65%8.81M | 295.00%312K | -55.29%1.5M | 0 | 454.68%7M | 1,577.25%50.79M | 87.22%-160K |
| Net issuance payments of debt | ---220K | --0 | ---7.5M | --0 | --0 | --0 | --0 | --0 | 112.97%491K | 97.12%-36K |
| Net common stock issuance | --3.46M | ---- | ---- | --0 | --0 | --0 | ---- | ---- | --47.72M | --0 |
| Proceeds from stock option exercised by employees | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -67.61%23K | --0 |
| Net other financing activities | ---- | ---- | ---- | 244.76%8.81M | 351.61%312K | 382.32%1.5M | --0 | 178.66%7M | 822.74%2.56M | -4,033.33%-124K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 144.67%3.67M | --1.43M | -207.14%-7.5M | -82.65%8.81M | 295.00%312K | -55.29%1.5M | --0 | 454.68%7M | 1,577.25%50.79M | 87.22%-160K |
| Net cash flow | ||||||||||
| Beginning cash position | -85.02%4.54M | -87.11%5.17M | -54.27%19.47M | 72.17%42.57M | -52.89%24.82M | -46.80%30.31M | 118.92%40.07M | 72.17%42.57M | 9.71%24.72M | 71.90%52.68M |
| Current changes in cash | 108.25%453K | 93.60%-624K | -471.66%-14.3M | -229.46%-23.1M | 47.10%-5.35M | -27.71%-5.49M | -125.22%-9.75M | 61.05%-2.5M | 715.49%17.84M | -70.79%-10.11M |
| End cash Position | -79.88%4.99M | -85.02%4.54M | -87.11%5.17M | -54.27%19.47M | -54.27%19.47M | -52.89%24.82M | -46.80%30.31M | 118.92%40.07M | 72.17%42.57M | 72.17%42.57M |
| Free cash flow | 50.67%-3.45M | 78.82%-2.07M | 28.29%-6.81M | 9.06%-31.91M | 43.11%-5.66M | 8.66%-6.99M | 0.44%-9.75M | -23.64%-9.5M | -24.58%-35.09M | -113.17%-9.95M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data